| Literature DB >> 35455269 |
Chia-Yu Huang1,2, Ching-Chan Lin3,4, Ching-Yun Hsieh3, Chen-Yuan Lin3, Tzu-Ting Chen3, Pei-Ching Wu5,6, Dung-Huan Liu6,7,8, Sio-Ian Tou9, Hung-Rong Yen2,5,10,11.
Abstract
Vaccination is the most effective intervention to prevent infection and subsequent complications from SARS-CoV-2. Because of their multiple comorbidities, the elderly population experienced the highest number of deaths from the COVID-19 pandemic. Although in most countries, older people have top priority for COVID-19 vaccines, their actual willingness and attitudes regarding vaccination are still unclear. Thus, we conducted a cross-sectional study to investigate their willingness, attitudes, awareness, and knowledge of COVID-19 through a web-based questionnaire after the first local outbreak of COVID-19 in Taiwan. A total of 957 questionnaires were completed, and 74.9% of elderly individuals were likely to receive COVID-19 vaccines. The results from a multiple logistic regression demonstrated that older people who need to visit the outpatient department and have a high level of concern about the safety of COVID-19 vaccines are prone to having a negative willingness to accept COVID-19 vaccines. The following items related to awareness of the COVID-19 pandemic were attributed to the acceptance of COVID-19 vaccines: "understanding the risk of being infected by SARS-CoV-2", "understanding the effectiveness of COVID-19 vaccines", "willingness to accept the COVID-19 vaccine for protecting others", and "safety of COVID-19 vaccines is a key factor for you to accept them". Furthermore, a positive association between COVID-19 vaccination and attitudes toward accepting booster doses of the COVID-19 vaccine was observed. Our results show that these factors could affect the willingness of older people to accept COVID-19 vaccines and that they are important for policymakers and medical staff to develop vaccination plans during the COVID-19 pandemic.Entities:
Keywords: COVID-19; Taiwan; elder; questionnaire; vaccine; willingness
Year: 2022 PMID: 35455269 PMCID: PMC9032573 DOI: 10.3390/vaccines10040520
Source DB: PubMed Journal: Vaccines (Basel) ISSN: 2076-393X
Basic characteristics of the participants stratified by willingness.
| Variables | Numbers | Positive willingness to Accept COVID-19 Vaccine 1 | Negative willingness to Accept COVID-19 Vaccine | |
|---|---|---|---|---|
| 74.9% | 25.1% | |||
|
| ||||
| Sex | 0.008 ** (0.086) | |||
| Male | 446 | 352 (78.9) | 94 (21.1) | |
| Female | 511 | 365 (71.4) | 146 (28.6) | |
| Age (years) | <0.001 *** (0.149) | |||
| 60–69 | 377 | 301 (79.8) | 76 (20.2) | |
| 70–79 | 267 | 205 (76.8) | 62 (23.2) | |
| 80–89 | 216 | 155 (71.8) | 61 (28.2) | |
| ≥90 | 97 | 56 (57.7) | 41 (42.3) | |
| Residential area | 0.036 * (0.083) | |||
| Community | 343 | 265 (77.3) | 78 (22.7) | |
| Nursing home | 337 | 236 (70.0) | 101 (30.0) | |
| Out-patient department | 277 | 216 (78.0) | 61 (22.0) | |
| CCI | 0.002 ** (0.099) | |||
| ≤4 | 816 | 626 (76.7) | 190 (23.3) | |
| ≥5 | 141 | 91 (64.5) | 50 (35.5) | |
| History of influenza vaccination | 0.003 ** (0.111) | |||
| Yearly | 535 | 406 (75.9) | 129 (24.1) | |
| Not yearly | 239 | 191 (79.9) | 48 (20.1) | |
| Never | 183 | 120 (65.6) | 63 (34.4) | |
| Preference of origin of influenza vaccine | <0.001 *** (0.169) | |||
| Nil | 799 | 573 (71.7) | 226 (28.3) | |
| Taiwan | 111 | 98 (88.3) | 13 (11.7) | |
| Oversea | 47 | 46 (97.9) | 1 (2.1) | |
| History of pneumococcal vaccination | 0.135 (0.084) | |||
| Yes | 360 | 260 (72.2) | 100 (17.8) | |
| Never | 597 | 457 (76.5) | 140 (23.5) |
1 We evaluated the willingness of accepting COVID-19 vaccines through participants responded with five options (very unlikely, somewhat unlikely, somewhat likely, very likely, and unsure). When a participant responded, “very likely” or “somewhat likely”, it was defined that the participant had a positive willingness of accepting COVID-19 vaccines. 2 The p-value was calculated using the chi-square test with effect size presented as coefficient of contingency. * p-value < 0.05; ** p-value < 0.01; *** p-value < 0.001. Abbreviation: COC, coefficient of contingency; CCI, Charlson Comorbidity Index.
Awareness of the COVID-19 pandemic and attitudes toward receiving the COVID-19 vaccines.
| Variables | Numbers | Positive willingness to Accept COVID-19 Vaccine 1 | Negative Willingness to Accept COVID-19 Vaccine | |
|---|---|---|---|---|
| 74.9% | 25.1% | |||
|
| ||||
| Understanding the risk of being infected by SARS-CoV-2 3 | <0.001 *** (0.391) | |||
| Low | 148 | 48 (32.4) | 100 (67.6) | |
| Middle | 92 | 68 (73.9) | 24 (26.1) | |
| High | 717 | 601 (83.8) | 116 (16.2) | |
| Understanding the severity of the COVID-19 pandemic | <0.001 *** (0.350) | |||
| Low | 134 | 47 (35.1) | 87 (64.9) | |
| Middle | 82 | 62 (75.6) | 20 (24.4) | |
| High | 741 | 608 (82.1) | 133 (17.9) | |
| Understanding the effectiveness of COVID-19 vaccines | <0.001 *** (0.438) | |||
| Low | 248 | 98 (39.5) | 150 (60.5) | |
| Middle | 126 | 102 (81.0) | 24 (19.0) | |
| High | 583 | 517 (88.7) | 66 (11.3) | |
| Understanding the complications of COVID-19 vaccines | <0.001 *** (0.340) | |||
| Low | 295 | 152 (51.5) | 143 (48.5) | |
| Middle | 134 | 110 (82.1) | 24 (17.9) | |
| High | 528 | 455 (86.2) | 73 (13.8) | |
| Willingness to accept the COVID-19 vaccine for protecting others | <0.001 *** (0.433) | |||
| Low | 281 | 123 (43.8) | 158 (56.2) | |
| Middle | 159 | 121 (76.1) | 38 (23.9) | |
| High | 516 | 472 (91.5) | 44 (8.5) | |
| Safety of COVID-19 vaccines is a key factor for you to accept them | <0.001 *** (0.125) | |||
| Low | 291 | 194 (66.7) | 97 (33.3) | |
| Middle | 124 | 96 (77.4) | 28 (22.5) | |
| High | 542 | 427 (78.8) | 115 (21.2) |
1 We evaluated the willingness of accepting COVID-19 vaccines through participants responded with 5 options (very unlikely, somewhat unlikely, somewhat likely, very likely, and unsure). When a participant responded, “very likely” or “somewhat likely”, it was defined that the participant had a positive willingness of accepting COVID-19 vaccines. 2 The p-value was calculated using the chi-square test with effect size presented as coefficient of contingency. 3 Participants responded using a 7-point scale, and higher values indicate greater levels. When they responded with 1–3, 4, or 5–7 on the scale, the level of that construct was defined as low, middle, or high, respectively. *** p-value < 0.001. Abbreviation: COC, coefficient of contingency.
Figure 1The percentages of positive and negative willingness to accept COVID-19 vaccine for each item in Table 2.
Possible factors affecting the willingness of elderly individuals to accept the COVID-19 vaccines.
| Variables | Numbers | Positive Willingness to Accept COVID-19 Vaccine 1 | Negative Willingness to Accept COVID-19 Vaccine | |
|---|---|---|---|---|
| 74.9% | 25.1% | |||
|
| ||||
| Availability of vaccination sites 3 | <0.001 *** (0.231) | |||
| Low | 360 | 222 (61.7) | 138 (38.3) | |
| Middle | 159 | 133 (83.6) | 26 (16.4) | |
| High | 438 | 362 (82.6) | 76 (17.4) | |
| Recommendation by family doctors | <0.001 *** (0.290) | |||
| Low | 235 | 123 (52.3) | 112 (47.7) | |
| Middle | 154 | 118 (76.6) | 36 (23.4) | |
| High | 568 | 476 (83.8) | 92 (16.2) | |
| Experiences from politicians | <0.001 *** (0.201) | |||
| Low | 550 | 370 (67.3) | 180 (22.7) | |
| Middle | 171 | 147 (86.0) | 24 (14.0) | |
| High | 236 | 200 (84.7) | 36 (15.3) | |
| Daily news from the media | <0.001 *** (0.202) | |||
| Low | 481 | 342 (71.1) | 139 (28.9) | |
| Middle | 187 | 147 (78.6) | 40 (21.4) | |
| High | 289 | 228 (78.9) | 61 (21.1) |
1 We evaluated the willingness of accepting COVID-19 vaccines through participants responded with five options (very unlikely, somewhat unlikely, somewhat likely, very likely, and unsure). When a participant responded, “very likely” or “somewhat likely”, it was defined that the participant had a positive willingness of accepting COVID-19 vaccines. 2 The p-value was calculated using the chi-square test with effect size presented as coefficient of contingency. 3 Participants responded using a 7-point scale, and higher values indicate greater levels. When they responded with 1–3, 4, or 5–7 on the scale, the level of that construct was defined as low, middle, or high, respectively. *** p-value < 0.001. Abbreviation: COC, coefficient of contingency.
Figure 2The percentages of positive and negative willingness to accept COVID-19 vaccine for each item in Table 3.
Knowledge of the COVID-19 pandemic and attitudes toward accepting booster doses of COVID-19 vaccines.
| Variables | Numbers | Positive Willingness to Accept COVID-19 Vaccine 1 | Negative Willingness to Accept COVID-19 Vaccine | |
|---|---|---|---|---|
| 74.9% | 25.1% | |||
|
| ||||
| Having information that SARS-CoV-2 could spread as influenza does yearly 3 | <0.001 *** (0.330) | |||
| Low | 350 | 193 (55.1) | 157 (44.9) | |
| Middle | 147 | 134 (91.2) | 13 (8.8) | |
| High | 460 | 390 (84.8) | 70 (15.2) | |
| Willingness to accept a booster dose of COVID-19 vaccines in the future | <0.001 *** (0.451) | |||
| Low | 329 | 147 (44.7) | 182 (55.3) | |
| Middle | 222 | 198 (89.2) | 24 (10.8) | |
| High | 406 | 372 (91.6) | 34 (8.4) |
1 We evaluated the willingness of accepting COVID-19 vaccines through participants responded with five options (very unlikely, somewhat unlikely, somewhat likely, very likely, and unsure). When a participant responded, “very likely” or “somewhat likely”, it was defined that the participant had a positive willingness of accepting COVID-19 vaccines. 2 p-value was calculated using the chi-square test with effect size presented as coefficient of contingency. 3 Participants responded using a 7-point scale, and higher values indicate greater levels. When they responded with 1–3, 4, or 5–7 on the scale, the level of that construct was defined as low, middle, or high, respectively. *** p-value < 0.001. Abbreviation: COC, coefficient of contingency.
Figure 3The percentages of a positive and negative willingness to accept COVID-19 vaccine for each item in Table 4.
Individual variables associated with positive willingness to accept the COVID-19 vaccines.
| Variables | Model 1 1 | Model 2 2 | Model 3 3 | Model 4 4 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Odds Ratio | 95% | Odds Ratio | 95% | Odds Ratio | 95% | Odds Ratio | 95% | |||||
| Sex | |||||||||||||
| Male | 446 | 1 | 1 | 1 | 1 | ||||||||
| Female | 511 | 0.71 | (0.52–0.97) | 0.033 * | 0.76 | (0.51–1.14) | 0.188 | 0.81 | (0.53–1.22) | 0.305 | 0.79 | (0.51–1.22) | 0.281 |
| Age (years) | |||||||||||||
| 60–69 | 377 | 1 | 1 | 1 | 1 | ||||||||
| 70–79 | 267 | 0.87 | (0.42–1.14) | 0.500 | 1.52 | (0.90–2.57) | 0.116 | 1.54 | (0.90–2.67) | 0.115 | 1.78 | (1.00–3.17) | 0.050 |
| 80–89 | 216 | 0.69 | (0.42–1.14) | 0.145 | 1.75 | (0.90–3.42) | 0.099 | 1.78 | (0.90–0.36) | 0.099 | 2.17 | (1.02–4.61) | 0.045 * |
| ≥90 | 97 | 0.39 | (0.20–0.77) | 0.007 ** | 0.97 | (0.39–2.46) | 0.973 | 1.00 | (0.38–2.64) | 0.650 | 1.20 | (0.43–3.34) | 0.735 |
| Residential area | |||||||||||||
| Community | 343 | 1 | 1 | 1 | 1 | ||||||||
| Nursing home | 337 | 0.90 | (0.58–1.41) | 0.652 | 2.08 | (1.11–3.90) | 0.023 * | 1.64 | (0.85–3.20) | 0.142 | 1.48 | (0.73–3.01) | 0.276 |
| Out-patient | 277 | 1.23 | (0.82–1.86) | 0.319 | 0.63 | (0.36–1.10) | 0.102 | 0.53 | (0.29–0.97) | 0.041 * | 0.47 | (0.25–0.91) | 0.026 * |
| CCI | |||||||||||||
| ≤4 | 816 | 1 | 1 | 1 | 1 | ||||||||
| ≥5 | 141 | 1.00 | (0.59–1.72) | 0.982 | 0.87 | (0.42–1.79) | 0.699 | 0.84 | (0.39–1.79) | 0.650 | 0.98 | (0.44–2.18) | 0.953 |
| History of | |||||||||||||
| Yearly | 535 | 1 | 1 | 1 | 1 | ||||||||
| Not yearly | 239 | 0.81 | (0.52–1.28) | 0.366 | 0.97 | (0.54–1.75) | 0.928 | 1.02 | (0.56–1.88) | 0.942 | 1.05 | (0.54–2.01) | 0.890 |
| Never | 183 | 0.38 | (0.24–0.61) | <0.001 *** | 0.48 | (0.22–0.88) | 0.018 * | 0.56 | (0.30–1.06) | 0.073 | 0.72 | (0.37–1.41) | 0.340 |
| Preference of origin of | |||||||||||||
| Nil | 799 | 1 | 1 | 1 | 1 | ||||||||
| Taiwan only | 111 | 0.81 | (0.52–1.28) | 0.002 ** | 1.98 | (0.90–4.37) | 0.091 | 2.07 | (0.93–4.65) | 0.077 | 2.08 | (0.88–4.91) | 0.094 |
| Oversea only | 47 | 0.38 | (0.24–0.61) | 0.007 ** | 11.76 | (1.43–97.16) | 0.022 * | 9.58 | (1.13–80.96) | 0.038 * | 5.07 | (0.60–42.96) | 0.137 |
| History of pneumococcal vaccination | |||||||||||||
| Yes | 360 | 1 | 1 | 1 | 1 | ||||||||
| Never | 597 | 0.84 | (0.56–1.24) | 0.374 | 0.80 | (0.47–1.39) | 0.434 | 0.78 | (0.45–1.37) | 0.391 | 0.86 | (0.47–1.59) | 0.868 |
| Understanding the risk of being infected by SARS-CoV-2 5 | |||||||||||||
| Low | 148 | 1 | 1 | 1 | |||||||||
| Middle | 92 | 4.73 | (2.07–10.79) | <0.001 *** | 4.00 | (1.70–9.45) | 0.002 ** | 3.39 | (1.34–8.60) | 0.01 * | |||
| High | 717 | 6.43 | (3.25–12.73) | <0.001 *** | 5.68 | (2.79–11.56) | <0.001 *** | 5.19 | (2.40–11.25) | <0.001 *** | |||
| Understanding the severity of the COVID-19 pandemic | |||||||||||||
| Low | 134 | 1 | 1 | 1 | |||||||||
| Middle | 82 | 1.62 | (0.66–4.02) | 0.295 | 1.48 | (0.57–3.85) | 0.424 | 1.14 | (0.41–3.22) | 0.801 | |||
| High | 741 | 0.74 | (0.34–1.63) | 0.457 | 0.61 | (0.27–1.39) | 0.237 | 0.54 | (0.22–1.35) | 0.187 | |||
| Understanding the effectiveness of COVID-19 vaccines | |||||||||||||
| Low | 248 | 1 | 1 | 1 | |||||||||
| Middle | 126 | 3.42 | (1.80–6.49) | <0.001 *** | 4.45 | (2.27–8.72) | <0.001 *** | 3.59 | (1.77–7.31) | <0.001 *** | |||
| High | 583 | 7.02 | (4.03–12.24) | <0.001 *** | 8.02 | (4.45–14.46) | <0.001 *** | 6.00 | (3.22–11.17) | <0.001 *** | |||
| Understanding the complications of COVID-19 vaccines | |||||||||||||
| Low | 295 | 1 | 1 | 1 | |||||||||
| Middle | 134 | 1.57 | (0.80–3.11) | 0.192 | 1.37 | (0.69–2.75) | 0.370 | 1.20 | (0.57–2.52) | 0.626 | |||
| High | 528 | 1.02 | (0.57–1.80) | 0.960 | 1.10 | (0.60–2.01) | 0.761 | 1.11 | (0.58–2.13) | 0.755 | |||
| Willingness to accept the COVID-19 vaccine for protecting others | |||||||||||||
| Low | 281 | 1 | 1 | 1 | |||||||||
| Middle | 159 | 2.75 | (1.58–4.78) | <0.001 *** | 2.61 | (1.45–4.69) | 0.001 ** | 2.46 | (1.32–4.60) | 0.005 ** | |||
| High | 516 | 12.93 | (7.54–22.17) | <0.001 *** | 10.60 | (6.07–18.69) | <0.001 *** | 8.56 | (4.63–15.82) | <0.001 *** | |||
| Safety of COVID-19 vaccines is a key factor for you to accept them | |||||||||||||
| Low | 291 | 1 | 1 | 1 | |||||||||
| Middle | 124 | 1.380 | (0.69–2.56) | 0.361 | 0.75 | (0.34–1.65) | 0.475 | 0.81 | (0.35–1.86) | 0.613 | |||
| High | 542 | 0.59 | (0.36–0.96) | 0.035 * | 0.43 | (0.25–0.75) | 0.003 * | 0.54 | (0.30–0.99) | 0.045 * | |||
| Availability of vaccination sites | |||||||||||||
| Low | 360 | 1 | 1 | ||||||||||
| Middle | 159 | 2.33 | (1.09–4.99) | 0.030 * | 1.68 | (0.74–3.82) | 0.215 | ||||||
| High | 438 | 1.05 | (0.60–1.82) | 0.875 ** | 0.83 | (0.45–1.51) | 0.533 | ||||||
| Recommendation by family doctors | |||||||||||||
| Low | 235 | 1 | 1 | ||||||||||
| Middle | 154 | 2.07 | (1.01–4.23) | 0.047 * | 1.90 | (0.88–4.09) | 0.101 | ||||||
| High | 568 | 2.68 | (1.50–4.78) | 0.001 ** | 1.80 | (0.96–3.38) | 0.068 | ||||||
| Experiences from politicians | |||||||||||||
| Low | 248 | 1 | 1 | ||||||||||
| Middle | 126 | 1.99 | 1.00–3.95 | 0.050 | 1.92 | (0.92–4.00) | 0.081 | ||||||
| High | 236 | 1.82 | 0.98–3.37 | 0.058 | 1.83 | (0.94–3.55) | 0.076 | ||||||
| Daily news from the media | |||||||||||||
| Low | 481 | 1 | 1 | ||||||||||
| Middle | 187 | 0.83 | 0.45–1.56 | 0.568 | 0.77 | (0.39–1.53) | 0.459 | ||||||
| High | 289 | 0.74 | 0.43–1.29 | 0.291 | 0.79 | (0.44–1.44) | 0.440 | ||||||
| Having information that SARS-CoV-2 could spread as influenza does yearly | |||||||||||||
| Low | 350 | 1 | |||||||||||
| Middle | 147 | 3.20 | (1.46–6.99) | 0.004 ** | |||||||||
| High | 460 | 1.01 | (0.57–1.76) | 0.987 | |||||||||
| Willingness to accept a booster dose of COVID-19 | |||||||||||||
| Low | 329 | 1 | |||||||||||
| Middle | 222 | 4.12 | (2.24–7.58) | <0.001 *** | |||||||||
| High | 406 | 5.09 | (2.66–9.75) | <0.001 *** | |||||||||
1 The independent variables were sex, age, CCI, residential area, history of influenza vaccination, preference of origin of influenza vaccine, and history of pneumococcal vaccination. 2 The independent variables were the factors in Model 1 plus understanding the risk of being infected by SARS-CoV-2, understanding the severity of the COVID-19 pandemic, understanding the effectiveness of COVID-19 vaccines, understanding the complications of COVID-19 vaccines, and willingness to accept the COVID-19 vaccine for protecting others, safety of COVID-19 vaccines is a key factor for you to accept them. 3 The independent variables were the factors in Model 2 plus the availability of vaccination sites, recommendation by family doctors, experiences from politician, and daily news form the media. 4 The independent variables were the factors in Model 3 plus having information that SARS-CoV-2 could spread as influenza does yearly and a willingness to accept a booster dose of COVID-19 vaccine in the future. 5 Participants responded using a 7-point scale, and higher values indicate greater levels. When they responded with 1–3, 4, or 5–7 on the scale, the level of that construct was defined as low, middle, or high, respectively. * p-value < 0.05; ** p-value < 0.01; *** p-value < 0.001. Abbreviation: CCI, Charlson Comorbidity Index score.